Azitra Inc

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The firm is involved in using engineered proteins and live bio therapeutic products that can be applied topically to treat diseases of the skin. It also offers a platform which is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen library of strains for drug like molecules. The company was founded by Azim Munivar and Travis Whitfill on January 2, 2014 and is headquartered in Branford, CT.

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company's platform and pipeline. The data are being presented on Friday, May 10, 2024, in two oral sessions entitled “Engineered Staphylococcus Epidermidis as a Protein Delivery System for Treating Skin Diseases” and “Staphylococcus epidermidis Strain Expressing LEKTI-D6 (A.

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended March 31, 2024, and provided a business update. Q1 2024 and Recent Business Highlights Advanced ATR-12's Phase 1b trial, activating sites, advancing central IRB approval, and identifying initial subjects with Netherton syndrome for dosing; primary endpoint.

Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company's platform and pipeline. The data will be presented on Friday, May 10, 2024, in two oral sessions entitled “Engineered Staphylococcus Epidermidis as a Protein Delivery System for Treating Skin Diseases” and “Staphylococcus epidermidis Strain Expressing LEKTI-D6 (ATR.

Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it will be presenting promising new preclinical data from its platform built (or optimized) to discover treatments for serious skin diseases at three upcoming scientific and medical conferences: ASGCT (American Society of Gene and Cell Therapy) Baltimore, MD Title: Engineered Staphylococcus Epidermi.

Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2023, and provided a business update. FY 2023 and Recent Business Highlights Completed an initial public offering, raising $7.5 million in gross proceeds. Obtained IND clearance of ATR-12 for a Phase 1b clinical trial in Netherton syndrome. Compl.

Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR) (the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the closing of its previously announced public offering of 16,667,000 shares of common stock, at a public offering price of $0.30 per share. Total gross proceeds from the offering, before deducting underwriting discounts and other offering expenses, were approximately $5 million. All.

Azitra, Inc. Announces Closing of Public Offering

Azitra (NYSEMKT: AZTR ) stock is falling on Wednesday after the pre-clinical biopharmaceutical company announced details for a public share offering. Azitra is selling 16,667,000 shares of AZTR stock for 30 cents per share.

Why Is Azitra (AZTR) Stock Down 70% Today?

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the pricing of an underwritten public offering of 16,667,000 shares of common stock. Each share of common stock is being sold at a public offering price of $0.30 per share for gross proceeds of approximately $5 million, before deducting underwriting discounts and offering expenses. All o.

Azitra, Inc. Announces Pricing of Public Offering

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent No. 11,850,267 covering future potential pipeline candidates for indications including ichthyosis vulgaris, titled “Methods and compositions for treating skin disease with recombinant microorganisms.” Travis Whitfill, Azitra's.

Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that management will present at the Dermatology Summit 2024, on Sunday, January 7, 2024 at 12:55pm PT and Biotech Showcase 2024, Monday, January 8, 2024 at 3:30pm PT, alongside the J.P. Morgan 42nd Annual Healthcare Conference. Dermatology Summit – January 7, 2024 Format: Azitra Inc., Corporate Pres.

Azitra, Inc. to Present at Biotech Showcase 2024 and the Dermatology Summit 2024, Alongside the J.P. Morgan Annual Healthcare Conference

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the third quarter ended September 30, 2023. Q3 and Recent Business Highlights Advanced its pipeline programs including ATR-12 (Netherton syndrome), ATR-04 (EGFRi-associated rash) and its Joint Development Agreement with Bayer Completed and filed post-IND, FDA commitments for cha.

Azitra, Inc. Announces Third Quarter 2023 Financial Results and Business Updates

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced today that management will present at the ThinkEquity Conference in New York City on October 19 at 3:00pm ET. The presentation will be streamed live and available for replay at: https://wsw.com/webcast/tep24/aztr/1700335. For more information about the conference or to schedule a one-on-one in person meet.

Azitra to Present at the ThinkEquity Conference

BRANFORD, Conn., Aug. 29, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced today that Travis Whitfill, COO, will present an overview of the Company at the H.C.

Azitra to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BRANFORD, Conn. , Aug. 14, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the second quarter ended June 30, 2023.

Azitra, Inc. Announces Second Quarter 2023 Financial Results and Business Updates

BRANFORD, Conn. , July 19, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the addition of two members to its board of directors, Barbara Ryan and John Schroer.

Azitra Adds Biotech Leaders Barbara Ryan and John Schroer to Its Board of Directors

BRANFORD, Conn. , July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the appointment of Travis Whitfill as Chief Operating Officer.

Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer

BRANFORD, Conn. , June 21, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR) (the "Company"), a biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products, today announced the closing of its initial public offering of 1,500,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $7,500,000, before deducting underwriting discounts and offering expenses.

Azitra, Inc. Announces Closing of Initial Public Offering

Azitra, Inc, a biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and topical live biotherapeutic products, has announced the pricing of its downsized initial public offering (IPO). Azitra plans to raise $7.5 million by offering 1.5 million of its common shares at a price of $5 per share.

Azitra prices IPO; shares to start trading today

BRANFORD, Conn. , June 15, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR) (the "Company"), a biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products, today announced the pricing of its initial public offering of 1,500,000 shares of common stock at a public offering price of $5.00 per share, for aggregate gross proceeds of $7,500,000 prior to deducting underwriting discounts and other offering expenses.

Azitra, Inc. Announces Pricing of Initial Public Offering

BranchOut Food Inc/OR

Cava Group, Inc.

Pixie Dust Technologies Inc

Surf Air Mobility Inc

There were no pricings this past week, as the sole scheduled deal delayed Azitra. Electric air travel company Surf Air Mobility filed for a direct listing on the NYSE. Pixie Dust Technologies, a Japanese maker of personal care devices and spatial materials, filed to raise $19 million at a $143 million market cap.

U.S. IPO Weekly Recap: No IPOs, But The Pipeline Gets A Pickup With 3 New Filers

Atmus Filtration Technologies Inc

CaliberCos Inc

FG Group Holdings Inc.

Renaissance IPO ETF

Renaissance International IPO ETF

Porsche Automobil Holding SE

Strong Global Entertainment Inc

Two small deals priced this past week, neither of which were eligible for inclusion in our IPO stats, while one issuer delayed to the week ahead. The week's news was driven by Cummins spin-off Atmus Filtration, which launched its $275 million IPO, and restaurant chain CAVA Group, which filed to raise $100 million.

U.S. IPO Weekly Recap: Atmus Launches $275 Million IPO And Restaurant Chain CAVA Joins The Pipeline

Airbnb

Black Spade Acquisition Co

Snowflake

VinFast Auto Ltd

No IPOs began trading or submitted initial filings this past week, as the sole scheduled deal, Strong Global Entertainment, was delayed to the week ahead. Vietnamese EV maker, VinFast, announced plans to merge with SPAC Black Spade Acquisition.

U.S. IPO Weekly Recap: Pipeline News Disrupts An Otherwise Silent Week For The IPO Market

Azitra has filed proposed terms for a $12 million U.S. IPO of its common stock. The firm is developing treatment candidates for various skin conditions.

IPO Update: Azitra Readies $12 Million IPO Effort

Azitra has filed to raise approximately $17 million in a U.S. IPO. The firm is an early-stage biopharma developing drug treatments for various skin conditions.

News for Azitra Inc Stock (AZTR)